In Brief: Endosonics
This article was originally published in The Gray Sheet
Endosonics: Receives go-ahead from FDA to market its Oracle Micro Plus family of combination percutaneous transluminal coronary angioplasty/ultrasound imaging catheters via premarket approval application supplement. Introduction in the U.S. is slated for the third quarter of 1995 with worldwide launch programs "planned prior to the end of this year," the firm states. The devices can both perform PTCA and image the lumen and artery wall. The supplement, submitted in November 1994, builds on the Pleasanton, California-based firm's September 1994 PMA for the first Oracle Micro system...
You may also be interested in...
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.